Select your language close

Dr Sara Ghorashian

Consultant Paediatric Haematologist and Honorary Senior Lecturer

Overview

Sara Ghorashian qualified from Oxford University and undertook haematology training at the Hammersmith and Royal Free Hospitals. She obtained a PhD at University College London (UCL) in the use of gene-engineered T cells for cancer immunotherapy. More recently, her post-doctoral studies at the UCL Great Ormond Street Institute of Child Health involved translation of CD19CAR T cells as therapy for childhood acute lymphoblastic leukaemia (ALL) from bench to bedside. Her research interests are cellular immunotherapy for haematological malignancies and T cell immunobiology.

She has clinical interests in paediatric malignant haematology, and leads on cell therapy and research within the department. She is a co-investigator on two CAR T cell studies for ALL, and actively involved in implementing new studies in order to improve outcomes for children with high risk or relapsed haematological malignancies.

Credentials

  • Paediatric malignant haematology
  • Cellular therapy for haematological malignancies
  • Development and optimisation of cellular therapies for haematological malignancies

  • BMBCh - Medicine (Oxford University)
  • MA (Hons) – Physiological Sciences (Oxford University)
  • MRCP - Royal College of Physicians, London
  • PhD – Immunology
  • FRCPath – Royal College of Pathologists, London

 

 

  • Development and optimisation of cellular therapies for haematological malignancies
  • T cell immunobiology

News & Publications

Khan AB, Carpenter B, Sousa PSE, Pospori C, Khorshed R, Griffin J, Veliça P, Zech M, Ghorashian S, et. al.  Redirection to the bone marrow improves T cell persistence and antitumor functions. J Clin Invest. doi: 10.1172/JCI97454 (epub ahead of print)

Vormittag P, Gunn R, Ghorashian S, Veraitch FS. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol.53:164-181.

Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S., et al. Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. Leukemia. DOI: 10.1038/leu.2017.39. 

Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, Ghorashian S., et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Science and Translational Medicine. 9(374). doi: 10.1126/scitranslmed.aaj2013. 

Holler A., Zech M., Ghorashian S., Pike R., et al. Expression of a dominant T cell receptor can reduce toxicity and enhance tumour protection of allogeneic T cell therapy. Haematologica, 101(4):482-90. 

Ghorashian, S., Pule, M., Amrolia, P. CD 19 chimeric antigen receptor therapy for haematological malignancies. British Journal of Haematology. 169(4), 463-78 

Ghorashian, S., Velica, P., Chua, I., McNicol, A-M., et al. CD8 T cell tolerance to a tumour associated self antigen is reversed by CD4 T cells engineered to express the same T cell receptor. Journal of Immunology 194(3), 1080-9 

Buchan, S.L., Manzo, T., Flutter, B., Rogel, A., Edwards, N., Zhang, L., Sivakumaran, S., Ghorashian, S., et al. OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ cells to exit quiescence. Journal of Immunology, 194(1), 125-33 

Zimbarra Cabrita, I., Abubaker, M., Layton, M., Ghorashian, S., et al. The association between tricuspid regurgitation velocity and 5-year survival in a North West London population of patients with sickle cell disease in the United Kingdom. British Journal of Haematology, 162(3): 400-408. 

Xue, S.-A., Gao, L., Ahmadi, M., Ghorashian, S., et al. Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. Oncoimmunology 2 (1), e22590 

Nicholson, E., Ghorashian, S., & Stauss, H. Improving TCR Gene Therapy for Treatment of Haematological Malignancies. Advances in Hematology, 2012, 404081 

Refer your child to Dr Sara Ghorashian

Use the form below to refer your child for treatment. A member of our team will be in touch within 2 working days.

Your Details
Relationship to Patient:
Preferred Language:
Patient Details
What is the purpose of your referral?
This is the end of the basic form. Please note, in order to progress with a referral we require a medical report for the patient, therefore if you have this information available now, please click the 'provide more info' button. Alternatively press submit and one of our team will be in touch.
Doctor Details
Any other Doctors involved in Patients care
Funding Details
Who is paying for your treatment?
Medical Records

Mandatory fields

Dr Sara Ghorashian Details

You can contact Dr Sara Ghorashian through Great Ormond Street Hospital below.

Share Dr Sara Ghorashian profile with someone:

Browse A-Z